Winrevair: Dosage Form, Projected Sales, NCE-1 Date | Sotatercept-Csrk

Winrevair

Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Sotatercept-Csrk
Innovator :

MERCK & CO., INC. (MSD)
Approval Date :

26-Mar-24
Data Exclusivity Expiry :

26-Mar-28
Market Exclusivity Expiry :

26-Mar-36
Dosage Form :

Subcutaneous Injection
Strength :

45 mg lyophilized cake or powder, 60 mg lyophilized cake or powder
Therapeutic Category :

Antihypertensive
Revenue ($M) :

419

Year-wise Projected Sales ($M) :

2025 :

1,746
2026 :

2,926
2027 :

4,145
2028 :

5,166
2029 :

6,130
2030 :

6,946
2031 :

7,669

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Winrevair

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?